These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 12615958)
1. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Brink C; Dahlén SE; Drazen J; Evans JF; Hay DW; Nicosia S; Serhan CN; Shimizu T; Yokomizo T Pharmacol Rev; 2003 Mar; 55(1):195-227. PubMed ID: 12615958 [TBL] [Abstract][Full Text] [Related]
2. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Bäck M; Dahlén SE; Drazen JM; Evans JF; Serhan CN; Shimizu T; Yokomizo T; Rovati GE Pharmacol Rev; 2011 Sep; 63(3):539-84. PubMed ID: 21771892 [TBL] [Abstract][Full Text] [Related]
3. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Chiang N; Serhan CN; Dahlén SE; Drazen JM; Hay DW; Rovati GE; Shimizu T; Yokomizo T; Brink C Pharmacol Rev; 2006 Sep; 58(3):463-87. PubMed ID: 16968948 [TBL] [Abstract][Full Text] [Related]
4. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Gronert K; Martinsson-Niskanen T; Ravasi S; Chiang N; Serhan CN Am J Pathol; 2001 Jan; 158(1):3-9. PubMed ID: 11141472 [TBL] [Abstract][Full Text] [Related]
5. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Singh RK; Gupta S; Dastidar S; Ray A Pharmacology; 2010; 85(6):336-49. PubMed ID: 20516735 [TBL] [Abstract][Full Text] [Related]
6. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Norel X; Brink C Pharmacol Ther; 2004 Jul; 103(1):81-94. PubMed ID: 15251228 [TBL] [Abstract][Full Text] [Related]
7. International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Brink C; Dahlén SE; Drazen J; Evans JF; Hay DW; Rovati GE; Serhan CN; Shimizu T; Yokomizo T Pharmacol Rev; 2004 Mar; 56(1):149-57. PubMed ID: 15001665 [TBL] [Abstract][Full Text] [Related]
8. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. McMahon B; Stenson C; McPhillips F; Fanning A; Brady HR; Godson C J Biol Chem; 2000 Sep; 275(36):27566-75. PubMed ID: 10869343 [TBL] [Abstract][Full Text] [Related]
9. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Levy BD; De Sanctis GT; Devchand PR; Kim E; Ackerman K; Schmidt BA; Szczeklik W; Drazen JM; Serhan CN Nat Med; 2002 Sep; 8(9):1018-23. PubMed ID: 12172542 [TBL] [Abstract][Full Text] [Related]
10. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils. Bae YS; Park JC; He R; Ye RD; Kwak JY; Suh PG; Ho Ryu S Mol Pharmacol; 2003 Sep; 64(3):721-30. PubMed ID: 12920210 [TBL] [Abstract][Full Text] [Related]
12. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Hauger RL; Grigoriadis DE; Dallman MF; Plotsky PM; Vale WW; Dautzenberg FM Pharmacol Rev; 2003 Mar; 55(1):21-6. PubMed ID: 12615952 [TBL] [Abstract][Full Text] [Related]
13. Mutations of serine 236-237 and tyrosine 302 residues in the human lipoxin A4 receptor intracellular domains result in sustained signaling. Kang Y; Taddeo B; Varai G; Varga J; Fiore S Biochemistry; 2000 Nov; 39(44):13551-7. PubMed ID: 11063592 [TBL] [Abstract][Full Text] [Related]
14. Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression. Maderna P; Godson C; Hannify G; Murphy M; Brady HR Am J Physiol Cell Physiol; 2000 Oct; 279(4):C945-53. PubMed ID: 11003574 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Chiang N; Arita M; Serhan CN Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):163-77. PubMed ID: 16125378 [TBL] [Abstract][Full Text] [Related]
20. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors. Forsman H; Dahlgren C Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]